Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7CQE

Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with AZD-7762

Summary for 7CQE
Entry DOI10.2210/pdb7cqe/pdb
DescriptorTyrosine-protein kinase Mer, CHLORIDE ION, 5-(3-fluorophenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide, ... (4 entities in total)
Functional Keywordstransferase inhibitor, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight68650.02
Authors
Park, T.H.,Lee, B.I. (deposition date: 2020-08-10, release date: 2020-11-04, Last modification date: 2023-11-29)
Primary citationPark, T.H.,Bae, S.H.,Bong, S.M.,Ryu, S.E.,Jang, H.,Lee, B.I.
Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development.
Int J Mol Sci, 21:-, 2020
Cited by
PubMed Abstract: Aberrant tyrosine-protein kinase Mer (MerTK) expression triggers prosurvival signaling and contributes to cell survival, invasive motility, and chemoresistance in many kinds of cancers. In addition, recent reports suggested that MerTK could be a primary target for abnormal platelet aggregation. Consequently, MerTK inhibitors may promote cancer cell death, sensitize cells to chemotherapy, and act as new antiplatelet agents. We screened an inhouse chemical library to discover novel small-molecule MerTK inhibitors, and identified AZD7762, which is known as a checkpoint-kinase (Chk) inhibitor. The inhibition of MerTK by AZD7762 was validated using an in vitro homogeneous time-resolved fluorescence (HTRF) assay and through monitoring the decrease in phosphorylated MerTK in two lung cancer cell lines. We also determined the crystal structure of the MerTK:AZD7762 complex and revealed the binding mode of AZD7762 to MerTK. Structural information from the MerTK:AZD7762 complex and its comparison with other MerTK:inhibitor structures gave us new insights for optimizing the development of inhibitors targeting MerTK.
PubMed: 33114206
DOI: 10.3390/ijms21217878
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.69 Å)
Structure validation

247536

PDB entries from 2026-01-14

PDB statisticsPDBj update infoContact PDBjnumon